Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” first quarter 2025 investor letter.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,115,507 | $71,180,502 | +13% | 0.06% |
| 2. | 52,620,000 | $67,554,699 | +38% | 0.01% | |
| 3. | 60,000,000 | $63,779,580 | +138% | 3.9% | |
| 4. | 37,500,000 | $48,160,573 | -22% | 0.03% | |
| 5. | D E Shaw D. E. Shaw | 619,562 | $39,534,252 | -26% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $57.62 | 15,746 | $907,237.28 | 733,719 | 2025-07-10 | Filing | |
| $56.74 | 4,254 | $241,380.47 | 749,465 | 2025-07-10 | Filing | |
| $57.08 | 208 | $11,871.81 | 733,719 | 2025-07-09 | Filing | |
| $56.43 | 19,792 | $1,116,783.39 | 733,927 | 2025-07-09 | Filing | |
| $55.74 | 16,402 | $914,214.68 | 733,719 | 2025-07-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 157,162 | $8,175,567 | 0.01% | |
| 2. | 102,000 | $5,305,020 | 0.23% | |
| 3. | 37,419 | $1,946,536 | 0.24% | |
| 4. | 21,857 | $1,180,278 | 0.03% | |
| 5. | 16,196 | $842,516 | 0.41% |
News See All
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target
H.C. Wainwright's Mitchell Kapoor maintained Halozyme Therapeutics Inc. (NASDAQ:HALO) at a $72 price target and a Buy rating on May 29.
11 Unstoppable Growth Stocks to Invest in Now
BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Bailey, and I will be your conference operator today.
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Karen, and I will be your conference operator today.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Jal [ph] and I'll be your conference operator today.
Billionaire Hedge Funds
